Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

AIMS: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon‐like peptide‐1 receptor agonist. MATERIALS AND METHODS: PIONEER 6 is a multinational, randomized, placebo‐controlled, double‐blind trial in patients with type 2 diabetes at high risk of CV...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Diabetes Obes Metab
Huvudupphovsmän: Bain, Stephen C., Mosenzon, Ofri, Arechavaleta, Rosario, Bogdański, Pawel, Comlekci, Abdurrahman, Consoli, Agostino, Deerochanawong, Chaicharn, Dungan, Kathleen, Faingold, Maria C., Farkouh, Michael E., Franco, Denise R., Gram, Jeppe, Guja, Cristian, Joshi, Pankaj, Malek, Rachid, Merino‐Torres, Juan F., Nauck, Michael A., Pedersen, Sue D., Sheu, Wayne H. ‐H., Silver, Robert J., Tack, Cees J., Tandon, Nikhil, Jeppesen, Ole K., Strange, Mette, Thomsen, Mette, Husain, Mansoor
Materialtyp: Artigo
Språk:Inglês
Publicerad: Blackwell Publishing Ltd 2018
Ämnen:
Clinical Trial Design
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587508/
https://ncbi.nlm.nih.gov/pubmed/30284349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13553
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk